Actions in Brazil
“We decided to file another patent opposition because the monopoly could be extended from 2017 to 2024, if this patent is granted. The granting of undue patents must be avoided to signal that market strategies seeking unlimited monopoly shall not undermine the sustainability of responses to public health needs”.
-- Renata Reis, coordinator of the Working Group on Intellectual Property of the Brazilian Network for the Integration of Peoples (GTPI/ Rebrip)
In Brazil, more than 50,000 people currently take lopinavir + ritonavir. The Working Group on Intellectual Property of the Brazilian Network for the Integration of Peoples (GTPI/ Rebrip) filed an opposition to Abbott patent claims on the medicine’s heat-stable form, which are not novel and do not contribute an inventive step.
Actions to Expand Access to Kaletra in Brazil
GTPI supports judicial decision annulling the patent for a HIV/AIDS medicine (links to www.patentes.org)
Link to press release (November 10, 2011) (em português) from o Grupo de Trabalho Sobre Propriedade Intelectual da Rede Brasiliera pela Integração dos Povos (GTPI/Rebrip)
MSF: Brazilians demand greater access to crucial HIV drug (links to msfaccess.org)
Working Group on International Property (GTPI) on Brazilian Patent Office's decision to prioritize examination of the patent application related to heat-stable ritonavir and lopinavir/ritonavir - December 15, 2011 (links to deolhonaspatentes.org.br)
ABIA publishes landscape of patent status and health sanitary registrations for HIV/AIDS treatments in Brazil (jn Portuguese), August 2012
Essential Action Factsheet- Access to Medicines in Brazil: Interference by the United States, September 21, 2007
Return to the Kaletra Campaign Homepage